Hematopoiesis News Volume 3.44 | Nov 6 2012

    0
    20

    Hematopoiesis News 3.44 November 6, 2012
    Hematopoiesis News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Hematopoiesis News on Twitter

    TOP STORY

    Mouse Embryonic Head as a Site for Hematopoietic Stem Cell Development
    Researchers report that, in parallel to the aorta-gonad-mesonephros region, the E10.5–E11.5 mouse head harbors bona fide hematopoietic stem cells (HSCs), as defined by long-term, high-level, multilineage reconstitution and self-renewal capacity in adult recipients, before HSCs enter the circulation. [Cell Stem Cell] Abstract

    Complimentary Wallchart: Human Hematopoietic Progenitors. Request Your Copy Today.

    PUBLICATIONS (Ranked by impact factor of the journal)

    LABORATORY RESEARCH

    The Transcriptional Landscape of Hematopoietic Stem Cell Ontogeny
    Scientists acquired the transcriptomes of developing hematopoietic stem cells (HSCs) purified from >2,500 murine embryos and adult mice. They found that embryonic hematopoietic elements clustered into three distinct transcriptional states characteristic of the definitive yolk sac, HSCs undergoing specification, and definitive HSCs. [Cell Stem Cell] Abstract | Graphical Abstract

    G9a/GLP-Dependent Histone H3K9me2 Patterning during Human Hematopoietic Stem Cell Lineage Commitment

    Investigators reported that in adult human hematopoietic stem and progenitor cells, histone H3 Lys 9 (H3K9me2) chromatin territories are absent in primitive cells and are formed de novo during lineage commitment. [Gene Dev] Abstract

    Delayed Development of Chronic Lymphocytic Leukemia in the Absence of Macrophage Migration Inhibitory Factor
    Researchers characterized the functional role of Migration inhibitory factor (MIF) in a chronic lymphocytic leukemia mouse model. For this purpose, they crossed Eμ-TCL1 mice with MIF knockout (MIF-/-) mice. The resulting TCL1+/wtMIF-/- mice showed a delayed onset of leukemia, reduced splenomegaly and hepatomegaly and a longer survival than TCL1+/wtMIFwt/wt controls. [Blood] Abstract

    Divergent Effects of Supraphysiological Notch Signals on Leukemia Stem Cells and Hematopoietic Stem Cells
    The Leukemia Stem Cell (LSC) hypothesis proposes that a subset of cells in the bulk leukemia population propagates the leukemia. Researchers tested the LSC hypothesis in a mouse model of Notch-induced T-cell acute lymphoblastic leukemia in which the tumor cells are largely CD4+CD8+ T cells. [Blood] Abstract

    Diabetes Impairs Stem Cell and Proangiogenic Cell Mobilization in Humans
    Investigators sought to assay mobilization of stem and proangiogenic cells in subjects with and without diabetes mellitus. [Diabetes Care] Abstract

    CIK Cells from Recurrent or Refractory AML Patients Can Be Efficiently Expanded In Vitro and Used for Reduction of Leukemic Blasts In Vivo
    Scientists investigated whether cytokine-induced killer (CIK) cells from recurrent or refractory acute myeloid leukemia (AML) patients with a high peripheral leukemia cell burdens could be expanded to a clinically usable number, and further evaluated their anti-tumor potentials in vitro and in vivo. [Exp Hematol] Abstract

    CLINICAL RESEARCH

    Initial Molecular Response at Three Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib
    The association between initial molecular response and longer-term outcomes with nilotinib was examined. Patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase from the phase II nilotinib registration study with available postbaseline BCR-ABL1 transcript assessments were included. [J Clin Oncol] Abstract

    Acute Toxicities of Unrelated Bone Marrow versus Peripheral Blood Stem Cell Donation: Results of a Prospective Trial from the NMDP
    Although peripheral blood stem cells (PBSC) have replaced bone marrow (BM) as the most common unrelated donor progenitor cell product collected, a direct comparison of concurrent PBSC vs. BM donation experiences has not been performed. Researchers report a prospective study of 2726 bone marrow and 6768 peripheral blood stem cells donors who underwent collection from 2004-2009. Pain and toxicities were assessed at baseline, during G-CSF administration, on the day of collection, within 48 hours of donation, and weekly until full recovery. [Blood] Abstract

    Influence of Enzyme and Transporter Polymorphisms on Trough Imatinib Concentration and Clinical Response in Chronic Myeloid Leukemia Patients

    Investigators explored the impact of genetic polymorphisms in cytochrome P450 enzymes and transporters on the plasma trough concentration of imatinib mesylate and clinical response in chronic myeloid leukemia. [Ann Oncol] Abstract

    StemSpan ACF: The WORLD'S FIRST Plasma Component-Free Hematopoietic Expansion Medium. Come learn more.

    REVIEWS

    Hematopoietic Cell Transplantation for Thalassemia: A Global Perspective
    The authors review the current status of bone marrow transplantation for thalassemia major with particular emphasis on a global prospective. [Biol Blood Marrow Transplant] Abstract

    INDUSTRY NEWS

    Del Mar Pharmaceuticals Expands Collaboration with Guangxi Wuzhou Pharmaceutical Company
    Del Mar Pharmaceuticals Ltd. announced a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company, a subsidiary of publicly traded Guangxi Wuzhou Zhongheng Group Co., Ltd for the development of VAL-083, known as “DAG for Injection” in China. DAG for Injection in China is approved by the Chinese State Food and Drug Administration as a cancer chemotherapy for the treatment of Chronic Myelogenous Leukemia and lung cancer. [Del Mar Pharmaceuticals] Press Release

    Stem Cell Research at UCSB Soars with New Lab Space and New Research Teams
    Campus leaders, dignitaries, scientists, and engineers gathered at UC Santa Barbara (UCSB) to celebrate the completion of a dream: 10,000 square feet of renovated laboratory space devoted to stem cell research. This was the grand opening ceremony and ribbon-cutting in celebration of UCSB’s Center for Stem Cell Biology and Engineering, part of the Neuroscience Research Institute. The California Institute for Regenerative Medicine contributed to the renovation with a $3.2 million grant that was matched by $3.2 million from UCSB. [UC Santa Barbara] Press Release

    POLICY NEWS

    National Institutes of Health (United States)

    Food and Drug Administration (United States)
     
    Center for Biologics Evaluation and Research (United States)
     
    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    EVENTS

    NEW Cancer Cell Metabolism and Systems Biology
    December 6, 2012
    New York City, United States

    Visit our events page to see a complete list of events in the hematopoietic community.

    JOB OPPORTUNITIES

    Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

    Product Manager – Hematopoietic (STEMCELL Technologies, Inc.)

    Product Quality Scientist (STEMCELL Technologies, Inc.)

    Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

    Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

    Scientist, Postdoctoral and Research Associate Positions (University of Miami – Sylvester Comprehensive Cancer Center)

    Postdoctoral Position – Impact of Inflammation on Hematopoiesis and Cancer (University of Murcia)

    Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

    Senior Lecturer – Cancer Stem Cells (The European Cancer Stem Cell Research Institute)

    Postdoctoral Position – Hematopoietic Stem Cell and Leukemia Research (City of Hope Beckman Research Institute) 

    Postdoctoral Position – Human Leukemic Stem Cells (University of Groningen)

    Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

    Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

    Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us

    Suite 201 – 375 West Fifth Avenue
    Vancouver, BC V5Y 1J6, Canada